Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for TFRC returned no results
Showing 1301 to 1350 of 2486 results for term

  1. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

    Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.

  2. Epiretinal brachytherapy for wet age-related macular degeneration (HTG279)

    Evidence-based recommendations on epiretinal brachytherapy for wet age related macular degeneration. This involves using radiation therapy used to destroy the new blood vessels.

  3. Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids (HTG523)

    Evidence-based recommendations on ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids in adults. This involves focusing high-intensity ultrasound energy at the fibroids through the skin of the abdomen.

  4. Renal replacement therapy and conservative management (NG107)

    This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.

  5. DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography (HTG594)

    Evidence-based recommendations on DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography.

  6. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  7. Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

    Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.

  8. Migraine prophylaxis: flunarizine (ESUOM33)

    Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making

  9. Social anxiety disorder: recognition, assessment and treatment (CG159)

    This guideline covers recognising, assessing and treating social anxiety disorder (also known as ‘social phobia’) in children and young people (from school age to 17 years) and adults (aged 18 years and older). It aims to improve symptoms, educational, occupational and social functioning, and quality of life in people with social anxiety disorder.

  10. Eltrombopag for treating chronic immune thrombocytopenia (TA293)

    Evidence-based recommendations on eltrombopag (Revolade) for treating chronic immune thrombocytopenia in adults.

  11. Antisocial personality disorder: prevention and management (CG77)

    This guideline covers principles for working with people with antisocial personality disorder, including dealing with crises (crisis resolution). It aims to help people with antisocial personality disorder manage feelings of anger, distress, anxiety and depression, and to reduce offending and antisocial behaviour.

  12. VAAFT for treating anal fistulae (MIB102)

    NICE has developed a medtech innovation briefing (MIB) on VAAFT for treating anal fistulae .

  13. Survivorship: What are the experiences of people who are living with, through and beyond a melanoma diagnosis in terms of survivorship and their disease journey?

    of people who are living with, through and beyond a melanoma diagnosis in terms of survivorship and their disease journey? Any...

  14. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

    Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.

  15. Kidney cancer (QS215)

    This quality standard covers diagnosing and managing renal cell carcinoma in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  16. Percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access (HTG597)

    Evidence-based recommendations on percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access in adults. This involves using radiofrequency energy, or heat and pressure, to join an artery and vein in the forearm to create a fistula for haemodialysis access.

  17. Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension (HTG741)

    Evidence-based recommendations on alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension. This involves putting alcohol into the wall of a renal artery to destroy renal nerves.

  18. Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment (HTG693)

    Evidence-based recommendations on removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. This involves surgically removing ovarian tissue before a treatment for cancer or other medical condition that can damage the ovaries (gonadotoxic treatment) begins. The ovarian tissue is then frozen to be reimplanted after the gonadotoxic treatment is finished, to restore fertility.

  19. Phrenic nerve pacing for congenital central hypoventilation syndrome (HTG725)

    Evidence-based recommendations on phrenic nerve pacing for congenital central hypoventilation syndrome. This involves direct stimulation of the phrenic nerve, to produce the inhalation phrase of breathing.

  20. Percutaneous balloon valvuloplasty for fetal critical aortic stenosis (HTG471)

    Evidence-based recommendations on percutaneous balloon valvuloplasty for fetal critical aortic stenosis. This involves placing a catheter into the baby’s heart, while the baby is still in the womb. The aim is to help the heart develop properly.

  21. Robot-assisted kidney transplant (HTG468)

    Evidence-based recommendations on robot-assisted kidney transplant in adults. This involves the surgeon using a robot to help with a kidney transplant.

  22. Prosthetic intervertebral disc replacement in the lumbar spine (HTG197)

    Evidence-based recommendations on prosthetic intervertebral disc replacement in the lumbar spine. This involves removing the damaged disc and inserting an artificial disc in its place.

  23. Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal (HTG503)

    Evidence-based recommendations on Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal in adults. This involves using the ileum to create a pouch on the inside of the abdominal wall to collect waste.

  24. Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor (HTG474)

    Evidence-based recommendations on unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor in adults. This involves applying ultrasound to a specific area on 1 side of the brain (thalamus).

  25. Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation (HTG772)

    Evidence-based recommendations on off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation. This involves inserting artificial chordae that help the mitral valve to close properly.

  26. Workplace health: long-term sickness absence and incapacity to work (PH19)

    This guideline has been updated and replaced by NICE guideline NG146.

  27. Immunosuppressive therapy for kidney transplant in adults (TA481)

    Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults. The therapies are basiliximab (Simulect), immediate-release tacrolimus (Adoport, Capexion, Modigraf, Prograf, Tacni, Vivadex), mycophenolate mofetil (Cellcept and non-branded versions), rabbit anti-human thymocyte immunoglobulin (Thymoglobuline), prolonged-release tacrolimus (Advagraf, Envarsus), mycophenolate sodium (Myfortic, Ceptava), sirolimus (Rapamune), everolimus (Certican) and belatacept (Nulojix).

  28. Percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain (HTG399)

    Evidence-based recommendations on percutaneous intradiscal radiofrequency treatment of the intervertebral disc nucleus for low back pain. This involves relieving low back pain by delivering heat energy to the damaged disc.

  29. Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.

  30. Digital technologies to support self-management of COPD: early value assessment (HTG736)

    Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.

  31. Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)

    Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.

  32. Slide sheets for moving or repositioning a person: late-stage assessment (HTG745)

    Late-stage assessment (LSA) guidance on slide sheets for moving or repositioning a person.

  33. Path Finder for freezing of gait in people with Parkinson's disease (MIB170)

    NICE has developed a medtech innovation briefing (MIB) on Path Finder for freezing of gait in people with Parkinson’s disease .

  34. Siponimod for treating secondary progressive multiple sclerosis (TA656)

    Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.

  35. Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA776)

    Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.

  36. Blood transfusion (QS138)

    This quality standard covers blood transfusion and reducing the requirements for blood transfusion in adults, young people and children aged 1 year and over. It describes high-quality care in priority areas for improvement. It does not cover use of tranexamic acid for surgery during pregnancy or labour or blood transfusion during pregnancy or labour.

  37. Galcanezumab for preventing migraine (TA659)

    Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.

  38. PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes (MIB312)

    NICE has developed a medtech innovation briefing (MIB) on PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes .

  39. Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early value assessment (HTG766)

    Early value assessment (EVA) guidance on digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis.

  40. URO17 for detecting bladder cancer (MIB250)

    NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .

  41. Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)

    This document describes the framework for setting out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA. It will also be useful to those developing PDAs in enabling them to undertake a self-assessment of the quality of their tools and processes

  42. Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

    This guideline covers the assessment, preparation, training and monitoring needed when using sedation in people aged under 19. It aims to help healthcare professionals decide when sedation is the most clinically and cost effective option for reducing pain and anxiety during operations for children and young people.

  43. Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis (HTG569)

    Evidence-based recommendations on cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis. This involves surgically removing visible cancer and bathing the abdominal cavity with heated chemotherapy fluid to reach any remaining cancer cells.

  44. Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia (HTG698)

    Evidence-based recommendations on percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. This involves making a hole between a blocked artery and a vein, allowing the blood to flow into the leg beyond the blockage.

  45. Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death (HTG460)

    Evidence-based recommendations on subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death. This involves placing a device under the skin of the chest, which detects and treats fast heartbeats called tachyarrhythmias.

  46. Intramedullary distraction for lower limb lengthening (HTG613)

    Evidence-based recommendations on intramedullary distraction for lower limb lengthening in children, young people and adults. This involves surgically inserting a metal lengthening device in the shorter leg.

  47. Coronary sinus narrowing device implantation for refractory angina (HTG600)

    Evidence-based recommendations on laparoscopic radical prostatectomy. This involves removing the prostate gland and some surrounding tissue using specialised instruments through small cuts in the abdomen (keyhole surgery).

  48. Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection (HTG634)

    Evidence-based recommendations on aortic remodelling hybrid stent insertion for acute type A aortic dissection. This involves inserting a stent with material sewed on one end into part of the aorta.

  49. Endoanchoring systems in endovascular aortic aneurysm repair (HTG625)

    Evidence-based recommendations on endoanchoring systems in endovascular aortic aneurysm repair. This involves using an anchoring device to hold a stent in place to prevent leaks in an aneurysm repair.

  50. Microwave ablation for treating liver metastases (HTG409)

    Evidence-based recommendations on microwave ablation for treating liver metastases in adults. This involves using heat energy to destroy cancer cells.